Clinical Trial Update: Tolerance of Intranasal Administration of OT in Prader-Willi Newborn Babies [Phase 1, Phase 2]

View source ↗

Summary

A completed Phase 1/2 trial evaluating the tolerability of intranasal oxytocin in newborns with Prader-Willi syndrome.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prader-willi Syndrome

Drugs mentioned

• Oxytocin (intranasal) (oxytocin)

Snippet

Sponsor: University Hospital, Toulouse | Conditions: Prader-Willi Syndrome | Phase 1, Phase 2 | Status: COMPLETED